Tag Archives: Eli Lilly

Alzheimer’s Disease: Solanezumab Drug Trial Flops (BBC News / Alzheimer’s and Dementia)

Summary The phase 3 EXPEDITION3 trial has been abandoned, as Solanezumab failed to slow cognitive decline in tests on around 2,000 patients with Alzheimer’s Disease. Several other amyloid-clearance drugs are going through trials apparently. Full Text Link Reference Walsh, F. … Continue reading

Posted in BBC News, For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

New Hopes for Disease-Modifying Pharmacological Dementia Treatment (BBC News / AAIC / ARUK)

Summary Trials of the drug Solanezumab were abandoned in apparent failure in 2012. More detailed examination of the data has since revealed evidence that this medication may have a role in slowing the pace of progression in Alzheimer’s Disease slightly, … Continue reading

Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Dementia Consortium (Alzheimer’s Research UK)

Summary The Dementia Consortium has been established to fund academic dementia research experts from the UK and overseas in their efforts to develop early research findings concerning Alzheimer’s Disease, and other forms of dementia, into validated drug targets. “The Dementia … Continue reading

Posted in Alzheimer’s Research UK, Charitable Bodies, For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments, Quick Insights, UK | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Solanezumab Trials Results for Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Summary Solanezumab is a monoclonal antibody which binds soluble amyloid preferentially and had shown some promise of promoting better clearance of amyloid-beta from the brain in pre-clinical studies. Two placebo controlled trials (EXPEDITION 1 and EXPEDITION 2) of 1012 and … Continue reading

Posted in For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Experiences of the Patient Journey into Alzheimer’s Disease (Alzheimer’s Society)

Summary This research report, from Lilly UK and the Alzheimer’s Society, explores the experience of progression through stages in the development of dementia, from the early signs to diagnosis and beyond. Full Text Link Reference The ‘patient journey’ for people … Continue reading

Posted in Acute Hospitals, Alzheimer's Society, Charitable Bodies, Community Care, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Management of Condition, National, Patient Care Pathway, Person-Centred Care, Personalisation, Practical Advice, Quick Insights, UK, Universal Interest | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Bapineuzumab: Alzheimer’s Drug Trials Halted (Healthcare Today UK)

Summary Two U.S. drug companies have halted trials of bapineuzumab, an experimental drug to treat Alzheimer’s Disease. The drug failed to produce any improvement in the symptoms of dementia sufferers. Pfizer Inc. and Johnson & Johnson had been testing bapineuzumab, which had been designed … Continue reading

Posted in For Doctors (mostly), For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged , , , , , , , , , , | Leave a comment